Current evidence on mesenchymal stem cell therapy for traumatic spinal cord injury: systematic review and meta-analysis

Cytotherapy ◽  
2020 ◽  
Author(s):  
Sathish Muthu ◽  
Madhan Jeyaraman ◽  
Arun Gulati ◽  
Arunabh Arora
Biology ◽  
2021 ◽  
Vol 10 (3) ◽  
pp. 230
Author(s):  
Louis D. V. Johnson ◽  
Mark R. Pickard ◽  
William E. B. Johnson

Animal models have been used in preclinical research to examine potential new treatments for spinal cord injury (SCI), including mesenchymal stem cell (MSC) transplantation. MSC transplants have been studied in early human trials. Whether the animal models represent the human studies is unclear. This systematic review and meta-analysis has examined the effects of MSC transplants in human and animal studies. Following searches of PubMed, Clinical Trials and the Cochrane Library, published papers were screened, and data were extracted and analysed. MSC transplantation was associated with significantly improved motor and sensory function in humans, and significantly increased locomotor function in animals. However, there are discrepancies between the studies of human participants and animal models, including timing of MSC transplant post-injury and source of MSCs. Additionally, difficulty in the comparison of functional outcome measures across species limits the predictive nature of the animal research. These findings have been summarised, and recommendations for further research are discussed to better enable the translation of animal models to MSC-based human clinical therapy.


PLoS Biology ◽  
2013 ◽  
Vol 11 (12) ◽  
pp. e1001738 ◽  
Author(s):  
Ana Antonic ◽  
Emily S. Sena ◽  
Jennifer S. Lees ◽  
Taryn E. Wills ◽  
Peta Skeers ◽  
...  

2019 ◽  
Vol 97 ◽  
pp. 9-22 ◽  
Author(s):  
Zahra Hassannejad ◽  
Mahmoud Yousefifard ◽  
Yaser Azizi ◽  
Shayan Abdollah Zadegan ◽  
Kiavash Sajadi ◽  
...  

2019 ◽  
Vol 32 (3) ◽  
pp. 308-316 ◽  
Author(s):  
Ömercan Albayrak ◽  
Tarık Emre Şener ◽  
Mehmet Erşahin ◽  
Suna Özbaş-Turan ◽  
Ceyda Ekentok ◽  
...  

2011 ◽  
Vol 3 (1) ◽  
pp. 100-106
Author(s):  
Hala Gabr ◽  
Osama Ghannam ◽  
Mohamed Reda Awad ◽  
Klaus von Wild ◽  
Wael Abo El-Kheir ◽  
...  

2015 ◽  
Vol 44 (3) ◽  
pp. 182-198 ◽  
Author(s):  
Jonviea D. Chamberlain ◽  
Sonja Meier ◽  
Luzius Mader ◽  
Per M. von Groote ◽  
Martin W.G. Brinkhof

Background/Aims: Mortality and longevity studies of spinal cord injury (SCI) are essential for informing healthcare systems and policies. This review evaluates the current evidence among people with SCIs worldwide in relation to the WHO region and country income level; demographic and lesion characteristics; and in comparison with the general population. Methods: A systematic review of relevant databases for original studies. Pooled estimates were derived using random effects meta-analysis, restricted to traumatic SCI. Results: Seventy-four studies were included. In-hospital mortality varied, with pooled estimates of 24.1% (95% confidence interval (CI) 14.1-38.0), 7.6% (95% CI 6.3-9.0), 7.0% (95% CI 1.5-27.4), and 2.1% (95% CI 0.9-5.0) in the WHO regions of Africa, the Americas, Europe and Western Pacific. The combined estimate for low- and middle-income countries was nearly three times higher than for high-income countries. Pooled estimates of first-year survival were 86.5% (95% CI 75.3-93.1), 95.6% (95% CI 81.0-99.1), and 94.0% (95% CI 93.3-94.6) in the Americas, Europe and Western Pacific. Pooled estimates of standardized mortality ratios in tetraplegics were 2.53 (2.00-3.21) and 2.07 (1.47-2.92) in paraplegics. Conclusion: This study found substantial variation in mortality and longevity within the SCI population, compared to the general population, and between WHO regions and country income level. Improved standardization and quality of reporting is needed to improve inferences regarding the extent to which mortality outcomes following an SCI are related to healthcare systems, services and policies.


2013 ◽  
Vol 2013 ◽  
pp. 1-6 ◽  
Author(s):  
Hai Liu ◽  
Edward M. Schwarz ◽  
Chao Xie

Mesenchymal stem cell (MSC) transplantation has shown tremendous promise as a therapy for repair of various tissues of the musculoskeletal, vascular, and central nervous systems. Based on this success, recent research in this field has focused on complex tissue damage, such as that which occurs from traumatic spinal cord injury (TSCI). As the critical event for successful exogenous, MSC therapy is their migration to the injury site, which allows for their anti-inflammatory and morphogenic effects on fracture healing, neuronal regeneration, and functional recover. Thus, there is a need for a cost-effective in vivo model that can faithfully recapitulate the salient features of the injury, therapy, and recovery. To address this, we review the recent advances in exogenous MSC therapy for TSCI and traumatic vertebral fracture repair and the existing challenges regarding their translational applications. We also describe a novel murine model designed to take advantage of multidisciplinary collaborations between musculoskeletal and neuroscience researchers, which is needed to establish an efficacious MSC therapy for TSCI.


Sign in / Sign up

Export Citation Format

Share Document